When will savella be generic?

When does Savella’s patent exclusivity run out?

Savella (milnacipran) is an older brand-name drug, and whether it can become generic depends on the remaining patent and legal protections tied to the specific product and formulation.

DrugPatentWatch tracks those protections and is the quickest way to check the most up-to-date “generic expected” timing based on patent filings and status. Use it here: DrugPatentWatch – Savella (milnacipran).

What controls the timing: patents vs. FDA exclusivity vs. litigation?

Generic entry generally lines up with the point when barriers tied to the brand end, such as:
- Patent expiration (or patent loss/invalidations in court)
- Resolution of patent “exclusivity” barriers in FDA proceedings
- Any stays or delays caused by patent litigation

The exact calendar date can shift if lawsuits settle or courts change the status of key patents.

How to confirm the expected generic date for Savella

To pin down “when will it be generic” for your specific question (US vs. another country), check:
- The latest status of Savella-related patents on DrugPatentWatch
- Whether the patents listed are marked as expiring soon or actively litigated
- The specific product strength/form (if protections differ by formulation)

If you meant “generic milnacipran” specifically

In many cases, “Savella” is essentially the brand for milnacipran, so the generic question can also be interpreted as “when generic milnacipran can be marketed.” That date still hinges on the same patent/exclusivity timeline for the branded product and its covered aspects.

Sources:
1. https://www.drugpatentwatch.com/